Stock Track | Arrowhead Pharmaceuticals Soars 5% on $200 Million Payment from Sarepta and Upcoming Earnings

Stock Track

Yesterday

Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock is soaring 5.02% in Tuesday's trading session, driven by a significant milestone payment and anticipation of its upcoming earnings report. The biotechnology company's shares are gaining momentum following news of a $200 million payment from Sarepta Therapeutics and the scheduled release of its fourth-quarter financial results.

The substantial payment from Sarepta Therapeutics was triggered by progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003, an investigational small-interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1). This development highlights the value of Arrowhead's technology and partnerships in the pharmaceutical industry, boosting investor confidence in the company's potential for future revenue streams.

Adding to the positive sentiment, Arrowhead Pharmaceuticals is set to report its fourth-quarter earnings after the market closes on Tuesday. Analysts expect the company to report earnings per share of ($0.11) for the quarter. The combination of the milestone payment and the imminent financial results is likely contributing to the stock's upward movement as investors position themselves ahead of the earnings announcement. Additionally, B. Riley Securities has reiterated a Buy rating on Arrowhead Pharmaceuticals with a price target of $61.00, further supporting the bullish outlook on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1182368358"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182368358\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182368358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 02:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182368358","market":"sg","top_or_hot":-1,"title":"Stock Track | Arrowhead Pharmaceuticals Soars 5% on $200 Million Payment from Sarepta and Upcoming Earnings","media":"Stock Track","content":"<p>Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock is soaring 5.02% in Tuesday's trading session, driven by a significant milestone payment and anticipation of its upcoming earnings report. The biotechnology company's shares are gaining momentum following news of a $200 million payment from Sarepta Therapeutics and the scheduled release of its fourth-quarter financial results.</p>\n\n<p>The substantial payment from Sarepta Therapeutics was triggered by progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003, an investigational small-interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1). This development highlights the value of Arrowhead's technology and partnerships in the pharmaceutical industry, boosting investor confidence in the company's potential for future revenue streams.</p>\n\n<p>Adding to the positive sentiment, Arrowhead Pharmaceuticals is set to report its fourth-quarter earnings after the market closes on Tuesday. Analysts expect the company to report earnings per share of ($0.11) for the quarter. The combination of the milestone payment and the imminent financial results is likely contributing to the stock's upward movement as investors position themselves ahead of the earnings announcement. Additionally, B. Riley Securities has reiterated a Buy rating on Arrowhead Pharmaceuticals with a price target of $61.00, further supporting the bullish outlook on the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Arrowhead Pharmaceuticals Soars 5% on $200 Million Payment from Sarepta and Upcoming Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Arrowhead Pharmaceuticals Soars 5% on $200 Million Payment from Sarepta and Upcoming Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-26 02:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock is soaring 5.02% in Tuesday's trading session, driven by a significant milestone payment and anticipation of its upcoming earnings report. The biotechnology company's shares are gaining momentum following news of a $200 million payment from Sarepta Therapeutics and the scheduled release of its fourth-quarter financial results.</p>\n\n<p>The substantial payment from Sarepta Therapeutics was triggered by progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003, an investigational small-interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1). This development highlights the value of Arrowhead's technology and partnerships in the pharmaceutical industry, boosting investor confidence in the company's potential for future revenue streams.</p>\n\n<p>Adding to the positive sentiment, Arrowhead Pharmaceuticals is set to report its fourth-quarter earnings after the market closes on Tuesday. Analysts expect the company to report earnings per share of ($0.11) for the quarter. The combination of the milestone payment and the imminent financial results is likely contributing to the stock's upward movement as investors position themselves ahead of the earnings announcement. Additionally, B. Riley Securities has reiterated a Buy rating on Arrowhead Pharmaceuticals with a price target of $61.00, further supporting the bullish outlook on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARWR","symbol_name":"Arrowhead Research Corporation","start_time":0,"source_url":"","article_id":"1182368358","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182368358","pubTimestamp":1764095181,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock is soaring 5.02% in Tuesday's trading session, driven by a significant milestone payment and anticipation of its upcoming earnings report. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARWR":"Arrowhead Research Corporation"},"translate_title":"个股追踪|Arrowhead Pharmaceuticals因Sarepta支付2亿美元及即将公布财报而飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (NASDAQ: ARWR) stock is soaring 5.02% in Tuesday's trading session, driven by a significant milestone payment and anticipation of its upcoming earnings report. The biotechnology company's shares are gaining momentum following news of a $200 million payment from Sarepta Therapeutics and the scheduled release of its fourth-quarter financial results.\nThe substantial payment from Sarepta Therapeutics was triggered by progress in the Phase 1/2 multiple ascending dose (MAD) clinical study of SRP-1003, an investigational small-interfering RNA (siRNA) therapeutic for type 1 myotonic dystrophy (DM1). This development highlights the value of Arrowhead's technology and partnerships in the pharmaceutical industry, boosting investor confidence in the company's potential for future revenue streams.\nAdding to the positive sentiment, Arrowhead Pharmaceuticals is set to report its fourth-quarter earnings after the market closes on Tuesday. Analysts expect the company to report earnings per share of ($0.11) for the quarter. The combination of the milestone payment and the imminent financial results is likely contributing to the stock's upward movement as investors position themselves ahead of the earnings announcement. Additionally, B. Riley Securities has reiterated a Buy rating on Arrowhead Pharmaceuticals with a price target of $61.00, further supporting the bullish outlook on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}